A phase I study of the natural killer T-cell ligand α-galactosylceramide (KRN7000) in patients with solid tumors

Clinical Cancer Research

Volumn 8, Issue 12, 2002, Pages 3702-3709

  Giaccone, Giuseppe ^a   Punt, Cornelis J A ^b   Ando, Yoshitaka ^c   Ruijter, Rita ^a   Nishi, Nobusuke ^a,c   Peters, Marlies ^b   Von Blomberg, B Mary E ^a   Scheper, Rik J ^a   Van der Vliet, Hans J J ^a   Van den Eertwegh, Alfons J M ^a   Roelvink, Marja ^d   Beijnen, Jos ^e   Zwierzina, Heinz ^f   Pinedo, Herbert M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c KIRIN BREWERY CO LTD   (Japan)

^d NDDO Oncology   (Netherlands)

^e SLOTERVAART HOSPITAL   (Netherlands)

^f UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

1 O (ALPHA GALACTOPYRANOSYL) 2 HEXACOSANOYLAMINO 1,3,4 OCTADECANETRIOL; CD3 ANTIGEN; CYTOKINE; GLYCOSPHINGOLIPID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LIGAND; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PATIENT; CELL ASSAY; CELL COUNT; CELL POPULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG TOLERANCE; FEMALE; HEALTH STATUS; HUMAN; INOCULATION; MALE; MONITORING; NATURAL KILLER CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SOLID TUMOR; T LYMPHOCYTE; TIME; TUMOR GROWTH;

ADULT; AGED; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CELL DIVISION; CELL SURVIVAL; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GALACTOSYLCERAMIDES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERFERON TYPE II; INTERLEUKIN-12; KILLER CELLS, NATURAL; LIGANDS; LYMPHOCYTE ACTIVATION; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTES;

EID: 0036896332     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Natori, T., Morita, M., Akimoto, K., and Koezuka, Y. Agelasphins, novel antitumor and immunostimulatory cerebrosides from the marine sponge Agelas mauritianus. Tetrahedron, 50: 2771-2784, 1994.
2. Morita, M., Motoki, K., Akimoto, K., Natori, T., Sakai, T., Sawa, E., Yamaji, K., Koezuka, Y., Kobayashi, E., and Fukushima, H. Structure-activity relationship of α-galactosylceramides against B 16-bearing mice. J. Med. Chem., 38: 2176-2187, 1995.
3. Kawano, T., Cui, J., Koezuka, Y., Toura, I., Kaneko, Y., Motoki, K., Ueno, H., Nakagawa, R., Sato, H., Kondo, E., Koseki, H., and Taniguchi, M. CD1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides. Science (Wash. DC), 278: 1626-1629. 1997.
4. Exley, M., Garcia, J., Balk, S. P., and Porcelli, S. Requirements for CD1d recognition by human invariant Vα24+ CD4-CD8-T cells. J. Exp. Med., 186: 109-120, 1997.
5. Spada, F. M., Koezuka, Y., and Porcelli, S. A. CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells. J. Exp. Med., 188: 1529-1534, 1998.
6. Brossay, L., Chioda, M., Burdin, N., Koezuka, Y., Casorati, G., Dellabona, P., and Kronenberg, M. CD1d-mediated recognition of an α-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J. Exp. Med., 188: 1521-1528, 1998.
7. Chen, H., and Paul, W. E. Cultured NK1.1+ CD4+ T cells produce large amounts of IL-4 and IFN-γ upon activation by anti-CD3 or CD1. J. Immunol., 159: 2240-2249, 1997.
8. Godfrey, D. I., Hammond, K. J., Poulton, L. D., Smyth, M. J., and Baxter, A. G. NKT cells: facts, functions and fallacies. Immunol. Today, 21: 573-583, 2000.
9. Kawano, T., Cui, J., Koezuka, Y., Toura, I., Kaneko, Y., Sato, H., Kondo, E., Harada, M., Koseki, H., Nakayama, T., Tanaka, Y., and Taniguchi, M. Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Vα14 NKT cells. Proc. Natl. Acad. Sci. USA. 95: 5690-5693, 1998.
10. Carnaud, C., Lee, D., Donnars, O., Park, S. H., Beavis, A., Koezuka, Y., and Bendelac, A. Cutting edge: Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J. Immunol., 163: 4647-4650, 1999.
11. Hayakawa, Y., Takeda, K., Yagita, H., Kakuta, S., Iwakura, Y., Van Kaer, L., Saiki, I., and Okumura, K. Critical contribution of IFN-γ and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of α-galactosylceramide. Eur. J. Immunol., 31: 1720-1727, 2001.
12. Nishimura, T., Kitamura, H., Iwakabe, K., Yahata, T., Ohta, A., Sato, M., Takeda, K., Okumura, K., Van Kaer, L., Kawano, T., Taniguchi, M., Nakui, M., Sekimoto, M., and Koda, T. The interface between innate and acquired immunity: Glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes. Int. Immunol., 12: 987-994, 2000.
13. Inoue, H., Koezuka, Y., Nishi, N., Osawa, M., Motoki, K., Kobayashi, E., Kabaya, K., Obuchi, M., Fukushima, H., and Mori, K. J. α-galactosylceramide (AGL-517) treatment protects mice from lethal irradiation. Exp. Hematol., 25: 935-944, 1997.
14. Nakagawa, R., Motoki, K., Ueno, H., Iijima, R., Nakamura, H., Kobayashi, E., Shimosaka, A., and Koezuka, Y. Treatment of hepatic metastasis of the colon26 adenocarcinoma with an α-galactosylceramide. KRN7000. Cancer Res., 58: 1202-1207, 1998.
15. Kobayashi, E., Motoki, K., Uchida, T., Fukushima, H., and Koezuka, Y. KRN7000, a novel immunomodulator, and its antitumor activities. Oncol. Res, 7: 529-534, 1995.
16. Nakagawa, R., Nagafune, I., Tazunoki, Y., Ehara, H., Tomura, H., Iijima, R., Motoki, K., Kamishohara, M., and Seki, S. Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by α-galactosylceramide in mice. J. Immunol., 166: 6578-6584, 2001.
17. Osman, Y., Kawamura, T., Naito, T., Takeda, K., Van Kaer, L., Okumura, K., and Abo, T. Activation of hepatic NKT cells and subsequent liver injury following administration of α-galactosylceramide. Eur. J. Immunol., 30: 1919-1928, 2000.
18. Nakagawa, R., Motoki, K., Nakamura, H., Ueno, H., Iijima, R., Yamauchi, A., Tsuyuki, S., Inamoto, T., and Koezuka, Y. Antitumor activity of α-galactosylceramide. KRN7000, in mice with EL-4 hepatic metastasis and its cytokine production. Oncol. Res., 10: 561-568, 1998.
19. Smyth, M. J., Thia, K. Y., Street, S. E., Cretney, E., Trapani, J. A., Taniguchi. M., Kawano, T., Pelikan, S. B., Crowe, N. Y., and Godfrey, D. I. Differential tumor surveillance by NK and NKT cells. J. Exp. Med., 191: 661-668, 2000.
20. Cui, J., Shin, T., Kawano, T., Sato, H., Kondo, E., Toura, I., Kaneko, Y., Koseki, H., Kanno, M., and Taniguchi, M. Requirement for Vα 14 NKT cells in IL-12-mediated rejection of tumors. Science (Wash. DC), 278: 1623-1626, 1997.
21. Kawano, T., Nakayama, T., Kamada, N., Kaneko, Y., Harada, M., Ogura, N., Akutsu, Y., Motohashi, S., Iizasa, T., Endo, H., Fujisawa, T., Shinkai, H., and Taniguchi, M. Antitumor cytotoxicity mediated by ligand-activated human Vα24 NKT cells. Cancer Res, 59: 5102-5105, 1999.
22. Metelitsa, L. S., Naidenko, O. V., Kant, A., Wu, H. W., Loza, M. J., Perussia, B., Kronenberg, M., and Seeger, R. C. Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells. J. Immunol., 167: 3114-3122, 2001.
23. Kitamura, H., Iwakabe, K., Yahata, T., Nishimura, S., Ohta, A., Ohmi, Y., Sato, M., Takeda, K., Okumura, K., Van Kaer, L., Kawano, T., Taniguchi, M., and Nishimura, T. The natural killer T (NKT) cell ligand α-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J. Exp. Med., 189: 1121-1128, 1999.
24. Tahir, S. M., Cheng, O., Shaulov, A., Koezuka, Y., Bubley, G. J., Wilson, S. B., Balk, S. P., and Exley, M. A. Loss of IFN-γ production by invariant NK T cells in advanced cancer. J. Immunol., 167: 4046-4050, 2001.
25. Matsuda, J. L., Naidenko, O. V., Gapin, L., Nakayama, T., Taniguchi, M., Wang, C. R., Koezuka, Y., and Kronenberg, M. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. J. Exp. Med., 192: 741-754, 2000.
26. Yang, O. O., Racke, F. K., Nguyen, P. T., Gausling, R., Severino, M. E., Horton, H. F., Byrne, M. C., Strominger, J. L., and Wilson, S. B. CD1d on myeloid dendritic cells stimulates cytokine secretion and cytolytic activity of Vα24JαQ T-cells: a feedback mechanism for immune regulation. J. Immunol., 165: 3759-3762, 2000.
27. + NK cells in vitro. J. Immunol., 165: 1659-1664, 2000.
28. Sharif, S., Arreaza, G. A., Zucker, P., Mi, Q. S., Sondhi, J., Naidenko, O. V., Kronenberg, M., Koezuka, Y., Delovitch, T. L., Gombert, J. M., Leite-De-Moraes, M., Gouarin, C., Zhu, R., Hameg, A., Nakayama, T., Taniguchi, M., Lepault, F., Lehuen, A., Bach, J. F., and Herbelin, A. Activation of natural killer T cells by α-galactosylceramide treatment prevents the onset of autoimmune type I diabetes. Nat. Med., 7: 1057-1062, 2001.
29. Hong, S., Wilson, M. T., Serizawa, I., Wu, L., Singh, N., Naidenko, O. B., Miura, T., Haba, T., Scherer, D. C., Wei, J., Kronenberg, M., Koezuka, Y., and Van Kaer, L. The natural killer T-cell ligand α-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat. Med., 7: 1052-1056, 2001.
30. Jahng, A. W., Maricic, I., Pedersen, B., Burdin, N., Naidenko, O., Kronenberg, M., Koezuka, Y., and Kumar, V. Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis. J. Exp. Med., 194: 1789-1799, 2001.
31. Singh, A. K., Wilson, M. T., Hong, S., Olivares-Villagomez, D., Du, C., Stanic, A. K., Joyce, S., Sriram, S., Koezuka, Y., and Van Kaer, L. Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J. Exp. Med., 194: 1801-1811, 2001.
32. Miyamoto, K., Miyake, S., and Yamamura, T. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature (Lond.), 413: 531-534, 2001.
33. Terabe, M., Matsui, S., Noben-Trauth, N., Chen, H., Watson, C., Donaldson, D. D., Carbone, D. P., Paul, W. E., and Berzofsky, J. A. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat. Immunol., 1: 515-520, 2000.
34. Toura, I., Kawano, T., Akutsu, Y., Nakayama, T., Ochiai, T., and Taniguchi, M. Cutting edge: Inhibition of experimental tumor metastasis by dendritic cells pulsed with α-galactosylceramide. J. Immunol., 163: 2387-2391, 1999.
35. Shin, T., Nakayama, T., Akutsu, Y., Motohashi, S., Shibata, Y., Harada, M., Kamada, N., Shimizu, C., Shimizu, E., Saito, T., Ochiai, T., and Taniguchi, M. Inhibition of tumor metastasis by adoptive transfer of IL-12-activated Vα14 NKT cells. Int. J. Cancer, 91: 523-528, 2001.